Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients

References

• 1 Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann. Intern. Med. 121, 676–683 (1994).
  Medline CASGoogle Scholar
• 2 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med. 167(13), 1414–1419 (2007).
  MedlineGoogle Scholar
• 3 Doecke CJ, Cosh DG, Gallus AS. Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response. Aust. NZ J. Med. 21(3), 319–324 (1991).
  Medline CASGoogle Scholar
• 4 Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326–331 (2008).
  Medline CASGoogle Scholar
• 5 Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563–2570 (2007).
  Medline CASGoogle Scholar
• 6 Kim HS, Lee SS, Oh M et al. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet. Genomics 19(2), 103–112 (2009).
  Medline CASGoogle Scholar
• 7 Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753–764 (2009).
  Medline CASGoogle Scholar
• 8 Wadelius M, Chen L, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23–34 (2007).
  Medline CASGoogle Scholar
• 9 Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285–2293 (2005).
  Medline CASGoogle Scholar
• 10 Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784–792 (2009).
  Medline CASGoogle Scholar
• 11 Kamali F, Khan TI, King BP et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. 75(3), 204–212 (2004).
  Medline CASGoogle Scholar
• 12 Biss TT, Avery PJ, Brandao LR et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 119(3), 868–873 (2012).
  Medline CASGoogle Scholar
• 13 Tham L-S, Goh B-C, Nafziger A et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9[ast]. Clin. Pharmacol. Ther. 80(4), 346–355 (2006).
  Medline CASGoogle Scholar
• 14 Cosgun E, Limdi NA, Duarte CW. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics 27(10), 1384–1389 (2011).
  Medline CASGoogle Scholar
• 15 Liu KE, Lo CL, Hu YH. Improvement of adequate use of warfarin for the elderly using decision tree-based approaches. Methods Inf. Med. 53(1), 47–53 (2014).
  Medline CASGoogle Scholar
• 16 Grossi E, Podda GM, Pugliano M et al. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. Pharmacogenomics 15(1), 29–37 (2014).
  CASGoogle Scholar
• 17 Tan SL, Li Z, Song GB et al. Development and comparison of a new personalized warfarin stable dose prediction algorithm in Chinese patients undergoing heart valve replacement. Pharmazie 67(11), 930–937 (2012).
  Medline CASGoogle Scholar
• 18 Van Schie RM, Wessels JA, Le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur. Heart J. 32(15), 1909–1917 (2011).
  Medline CASGoogle Scholar
• 19 Li X, Liu R, Yan H et al. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. J. Clin. Pharmacol. 4(10), 392 (2014).
  Google Scholar
• 20 Kimmel SE, French B, Kasner SE et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369(24), 2283–2293 (2013).
  Medline CASGoogle Scholar
• 21 Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294–2303 (2013).
  Medline CASGoogle Scholar
• 22 Perera MA, Cavallari LH, Limdi NA et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382(9894), 790–796 (2013).
  Medline CASGoogle Scholar
• 23 Takeuchi F, Mcginnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
  MedlineGoogle Scholar
• 24 Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 12(1), 125–134 (2011).
  CASGoogle Scholar
• 25 Bodin L, Verstuyft C, Tregouet DA et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106(1), 135–140 (2005).
  Medline CASGoogle Scholar
• 26 Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383–391 (2001).
  Medline CASGoogle Scholar
• 27 Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol. 72(6), 948–957 (2011).
  Medline CASGoogle Scholar
• 28 Van Schie RM, Wessels JA, Le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur. Heart J. 32(15), 1909–1917 (2011).
  Medline CASGoogle Scholar
• 29 Verhoef TI, Ragia G, De Boer A et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N. Engl. J. Med. 369(24), 2304–2312 (2013).
  Medline CASGoogle Scholar